TrialGynecologic oncology2015

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

Robert L Coleman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.